CD44v6, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD44v6, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD44v6, Human |
| Clone | REA706 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | Vio Bright B515 conjugate |
| Size | 100 tests in 200 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD44v6 Antibody, anti-human, Vio® Bright B515, REAfinity™. Clone REA706 recognizes the CD44v6 antigen. CD44 is the receptor for hyaluronic acid (HA), which plays an important role in cell migration, tumor growth, and progression. CD44 is involved in the modification of the activity of receptors including MET and the ERBB family of tyrosine kinases. CD44 is a marker for many types of cancer stem cells (CSC), including breast CSCs that possess higher tumorigenicity and metastatic potential, colorectal, pancreatic, and prostate CSCs. In addition, expression was observed in several cancers as well as on carcinoma cell lines. Here, CD44 plays a role in cancer cell migration and matrix adhesion in response to a cellular microenvironment, thus enhancing cellular aggregation and tumor cell growth. CD44 is also expressed on mesodermal cells, such as hematopoietic, fibroblastic, and glial cells. | Additional information: Clone REA706 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | CDw44, Epican, ECMR-III, PGP-I, CSPG9, EMCR III, HCELL, HUTCH-I, H-CAM |
| Gene, Accession # | Gene ID: 960 |
| Catalog # | 130-130-173 |
| Price | $482 |
| Order / More Info | CD44v6, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Aruffo, A. et al. (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313. | Al-Hajj, M. et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100: 3983-3988. | Collins, A. T. et al. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65: 10946-10951. | Patrawala, L. et al. (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696-1708. | Dalerba, P. et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U.S.A. 104: 10158-10163. | Wang, L. et al. (2013) Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemoradiotherapy. Int. J. Biol. Sci. 9 (5): 472-479. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies